Key result
Adjuvant mitotane was associated with prolonged recurrence-free survival in patients with resected adrenocortical carcinoma compared to untreated controls (control group 1 HR 2.98; 95% CI 1.75-5.09; P<0.0001).
Why the study?
Does adjuvant mitotane improve recurrence-free survival in patients with radically resected adrenocortical carcinoma?
Population
162 patients with radically resected adrenocortical carcinoma who did not recur or die after a landmark…
Comparison
Adjuvant mitotane therapy vs No adjuvant strategy
Design
Case-control
Follow-up
9 additional years
Authors
Loading...
May support adjuvant mitotane after radical resection; leaves open need for randomized confirmation.
Case-Control (n=162)
Yes
Does adjuvant mitotane improve recurrence-free survival in patients with radically resected adrenocortical carcinoma?
Hazard Ratio: 2.98 (95% CI 1.75–5.09)
p-value: p=<0.0001
Adjuvant mitotane therapy is associated with prolonged recurrence-free survival in patients with radically resected adrenocortical carcinoma.
Berruti et al. (2017) conducted a case-control in Radically resected adrenocortical carcinoma (ACC) (n=162). Adjuvant mitotane vs. No adjuvant strategy / left untreated after surgery was evaluated on Recurrence-free survival (RFS) (HR 2.98, 95% CI 1.75 to 5.09, p=<0.0001). Adjuvant mitotane was associated with prolonged recurrence-free survival in patients with resected adrenocortical carcinoma compared to untreated controls (control group 1 HR 2.98; 95% CI 1.75-5.09; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: